These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37453848)

  • 1. Clinical impact of multimodal treatment including chemoradiotherapy, conversion surgery and postoperative chemotherapy for borderline resectable and unresectable locally advanced pancreatic cancer without disease progression after gemcitabine plus nab-paclitaxel.
    Umezawa R; Mizuma M; Nakagawa K; Yamamoto T; Takahashi N; Suzuki Y; Kishida K; Omata S; Unno M; Jingu K
    Pancreatology; 2023 Sep; 23(6):650-656. PubMed ID: 37453848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
    Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
    Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer.
    Yamada S; Fujii T; Yokoyama Y; Kawashima H; Maeda O; Suzuki K; Okada T; Ono E; Yamaguchi J; Takano N; Takami H; Hayashi M; Niwa Y; Hirooka Y; Ito Y; Naganawa S; Ando Y; Nagino M; Goto H; Kodera Y
    Cancer Chemother Pharmacol; 2018 May; 81(5):815-821. PubMed ID: 29502139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 Trial): study protocol for a single arm phase II study.
    Takano N; Yamada S; Hirakawa A; Yokoyama Y; Kawashima H; Maeda O; Okada T; Ohno E; Yamaguchi J; Ishikawa T; Sonohara F; Suenaga M; Takami H; Hayashi M; Niwa Y; Hirooka Y; Ito Y; Naganawa S; Ando Y; Nagino M; Goto H; Fujii T; Kodera Y
    Nagoya J Med Sci; 2019 May; 81(2):233-239. PubMed ID: 31239592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent Nab-paclitaxel and Radiotherapy: Novel Radiosensitization for Borderline Resectable or Unresectable Pancreatic Cancer.
    Arscott WT; Nead KT; Bear A; Venigalla S; Shabason J; Lukens JN; Plastaras JP; Wojcieszynski A; Metz J; O'Hara M; Reiss KA; Teitelbaum U; Loaiza-Bonilla A; Drebin J; Lee MK; Shroff SG; Ben-Josef E
    Am J Clin Oncol; 2021 Sep; 44(9):469-474. PubMed ID: 34310350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Cancer.
    Takada R; Ikezawa K; Daiku K; Maeda S; Abe Y; Urabe M; Kai Y; Yamai T; Fukutake N; Nakabori T; Uehara H; Ashida R; Akita H; Takahashi H; Teshima T; Ohkawa K
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience.
    Leone F; Gatti M; Massucco P; Colombi F; Sperti E; Campanella D; Regge D; Gabriele P; Capussotti L; Aglietta M
    Cancer; 2013 Jan; 119(2):277-84. PubMed ID: 22778019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study.
    Ushida Y; Inoue Y; Oba A; Mie T; Ito H; Ono Y; Sato T; Ozaka M; Sasaki T; Saiura A; Sasahira N; Takahashi Y
    Ann Surg Oncol; 2022 Aug; 29(8):5038-5050. PubMed ID: 35294658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma.
    Reni M; Zanon S; Balzano G; Passoni P; Pircher C; Chiaravalli M; Fugazza C; Ceraulo D; Nicoletti R; Arcidiacono PG; Macchini M; Peretti U; Castoldi R; Doglioni C; Falconi M; Partelli S; Gianni L
    Eur J Cancer; 2018 Oct; 102():95-102. PubMed ID: 30149366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer.
    Shabason JE; Chen J; Apisarnthanarax S; Damjanov N; Giantonio B; Loaiza-Bonilla A; O'Dwyer PJ; O'Hara M; Reiss KA; Teitelbaum U; Wissel P; Drebin JA; Vollmer C; Kochman M; Mick R; Vergara N; Jhala N; Doucette A; Lukens JN; Plastaras JP; Metz JM; Ben-Josef E
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):609-614. PubMed ID: 29362902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy following FOLFIRINOX in Patients with Unresectable Pancreatic Cancer: A Single-Institution, Retrospective Analysis.
    Hayuka K; Okuyama H; Murakami A; Okita Y; Nishiuchi T; Okano K; Suzuki Y; Tsuji A
    Chemotherapy; 2021; 66(3):58-64. PubMed ID: 34284397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer.
    Tsujimoto A; Sudo K; Nakamura K; Kita E; Hara R; Takayama W; Ishii H; Yamaguchi T
    Sci Rep; 2019 Nov; 9(1):16187. PubMed ID: 31700023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple modal treatment comprising with proton beam radiation, hyperthermia, and gemcitabine/nab-paclitaxel for locally advanced pancreatic cancer: a phase I/II study protocol (TT-LAP trial).
    Shimomura O; Endo M; Makishima H; Yamada T; Hashimoto S; Numajiri H; Miyazaki Y; Doi M; Furuya K; Takahashi K; Moriwaki T; Hasegawa N; Yamamoto Y; Niisato Y; Kobayashi M; Mizumoto M; Nakai K; Saito T; Hoshiai S; Saida T; Mathis BJ; Mori K; Nakajima T; Tsuchiya K; Sakurai H; Oda T
    BMC Cancer; 2023 Jul; 23(1):624. PubMed ID: 37403011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors in conversion surgery following nab-paclitaxel with gemcitabine and subsequent chemoradiotherapy for unresectable locally advanced pancreatic cancer: Results of a dual-center study.
    Igarashi T; Yamada S; Hoshino Y; Murotani K; Baba H; Takami H; Yoshioka I; Shibuya K; Kodera Y; Fujii T
    Ann Gastroenterol Surg; 2023 Jan; 7(1):157-166. PubMed ID: 36643365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel.
    Ide Y; Otsuka T; Shimokawa M; Koga F; Ueda Y; Nakazawa J; Komori A; Otsu S; Arima S; Fukahori M; Makiyama A; Shinohara Y; Ueno S; Taguchi H; Honda T; Shibuki T; Nio K; Ureshino N; Mizuta T; Mitsugi K; Shirakawa T
    Anticancer Res; 2023 Apr; 43(4):1817-1826. PubMed ID: 36974805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1).
    Gao S; Zhu X; Shi X; Cao K; Bian Y; Jiang H; Wang K; Guo S; Zhang H; Jin G
    Radiat Oncol; 2019 Mar; 14(1):52. PubMed ID: 30917842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study.
    Zong Y; Yuan J; Peng Z; Lu M; Wang X; Shen L; Zhou J
    J Cancer Res Clin Oncol; 2021 May; 147(5):1529-1536. PubMed ID: 33191450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of a locally advanced unresectable pancreatic cancer patient with interstitial pneumonitis by conversion surgery following gemcitabine plus nab-paclitaxel chemotherapy: A case report.
    Yokota T; Takano S; Yoshitomi H; Kagawa S; Furukawa K; Takayashiki T; Kuboki S; Suzuki D; Sakai N; Nojima H; Mishima T; Nakadai E; Ohtsuka M
    Mol Clin Oncol; 2019 Apr; 10(4):419-424. PubMed ID: 30931110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early detection of venous thromboembolism after the initiation of chemotherapy predicts a poor prognosis in patients with unresectable metastatic pancreatic cancer who underwent first-line chemotherapy with gemcitabine plus nab-paclitaxel.
    Yamai T; Ikezawa K; Hiraga E; Kawamoto Y; Hirao T; Higashi S; Daiku K; Maeda S; Abe Y; Urabe M; Kai Y; Takada R; Nakabori T; Fukutake N; Uehara H; Fujita M; Ohkawa K
    PLoS One; 2022; 17(3):e0264653. PubMed ID: 35231078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.